The US Food and Drug Administration (FDA) has granted emergency use authorization to Eli Lilly's combination antibody therapy to fight COVID. The therapy helped cut the risk of hospitalization and death in COVID-19 patients by how much percent?
The US Food and Drug Administration (FDA) has granted emergency use authorization to Eli Lilly's combination antibody therapy to fight COVID. The therapy helped cut the risk of hospitalization and death in COVID-19 patients by how much percent? Correct Answer 70
The correct answer is 70%.
- The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Eli Lilly's combination antibody therapy to fight COVID.
- The therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalization and death in COVID-19 patients by 70%.
- This therapy is authorized for the treatment of mild to moderate COVID-19 in patients aged 12 and above.
মোঃ আরিফুল ইসলাম
Feb 20, 2025